Impact of Telemedicine on Health Expenditures During the COVID-19 Pandemic in Japan: Quasi-Experimental Study.

Impact of Telemedicine on Health Expenditures During the COVID-19 Pandemic in Japan: Quasi-Experimental Study.

Publication date: Sep 23, 2025

The effects of telemedicine on health expenditures and health outcomes are an important policy question. Many countries loosened regulations on the use of telemedicine during the COVID-19 pandemic, thereby offering an opportunity to evaluate these effects via a natural experiment. This study aimed to assess the effect of greater telemedicine use on area-level health expenditures and health outcomes related to common chronic conditions in Japan during the COVID-19 pandemic. We compared prefectures (area levels of government) with higher prepandemic telemedicine rates (fiscal year [FY] 2019) versus those with lower rates and conducted a difference-in-differences analysis of the change in prefecture-level health expenditures from FY2017 to FY2022 and health outcomes from FY2017 to FY2021. The participants were the total population in Japan from FY2017 to FY2022 (n=126 million), and the exposure was the increase in telemedicine use following the government’s relaxation of restrictions on telemedicine use as an exceptional measure during the COVID-19 pandemic. Our main outcomes were the share of outpatient claims that were for telehealth services; total, inpatient, and outpatient annual prefecture-level health expenditures; all-cause mortality, glycated hemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol. Treatment prefectures (n=15, population of 62 million) were defined as those with greater-than-median telemedicine use before the pandemic, while control prefectures (n=32, population of 64 million) were defined as those with less-than-median telemedicine use. Treatment and control prefectures shared similar demographic characteristics before the pandemic. The growth in telemedicine after 2020 as a share of outpatient claims increased among the treatment prefectures by 0. 35 percentage points more than among control prefectures, which represented more than a threefold increase in telemedicine use compared to the prepandemic median. In difference-in-differences analyses, this difference was associated with a 1. 0% relative decrease (95% CI 0. 3%-1. 8%) in total health expenditure (P=. 006) and a 1. 1% relative decrease (95% CI 0. 2%-2. 0%) in inpatient expenditure (P=. 02). Outpatient expenditures showed no significant difference as a result of increased telemedicine adoption. Most health outcomes-all-cause mortality, glycated hemoglobin, systolic blood pressure, diastolic blood pressure, and low-density lipoprotein cholesterol-did not show any significant changes. Areas in Japan with greater expansion of telemedicine use during the pandemic experienced a significant decrease in both inpatient and total health care spending compared with areas with less telemedicine use, without harming health outcomes.

Open Access PDF

Concepts Keywords
Japan cost containment
Lipoprotein COVID-19
Outpatient COVID-19
Threefold Female
Health Expenditures
health reform
health spending
Humans
Japan
Male
Middle Aged
Pandemics
SARS-CoV-2
Telemedicine
telemedicine

Semantics

Type Source Name
disease MESH COVID-19 Pandemic
disease MESH chronic conditions
disease IDO blood
drug DRUGBANK Methylphenidate
disease MESH anxiety disorders
disease MESH depression
disease MESH ischemic stroke
disease MESH medication errors
disease IDO country
disease MESH emergencies
disease MESH lifestyle
disease IDO intervention

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *